

PUMA BIOTECHNOLOGY, INC.  
Form DEFA14A  
January 07, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14A**  
**Proxy Statement Pursuant to Section 14(a) of the**  
**Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under Rule 14a-12

**PUMA BIOTECHNOLOGY, INC.**

**(Name of the Registrant as Specified In Its Charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

On January 7, 2016, Puma Biotechnology, Inc. issued the following investor presentation.































A whistleblower  
from  
PPD,  
Ann  
Marie  
Cisneros

a  
clinical  
trial  
associate  
for  
PPD

testified  
that she sent evidence of fraud to PPD management, which was ignored

[b]ased  
upon what I observed and learned in monitoring the Kirkman-Campbell site, Dr.  
Kirkman-Campbell indeed had engaged in fraud . . . I knew it, PPD knew it

Cisneros Testimony: [http://www.circare.org/foia5/cisneros\\_testimony\\_20070213.pdf](http://www.circare.org/foia5/cisneros_testimony_20070213.pdf)\*

Eshelman  
denied before Congress that fraud had occurred at the time despite Cisneros e-mail  
to PPD management summarizing fraudulent practices and red flags

Eshelman s  
Video Testimony:

Part 1: <https://www.youtube.com/watch?v=mzOBIX7hLMs>\*

Part 2: <https://www.youtube.com/watch?v=GeM9ZDMBc0M>\*

Part 3: <https://www.youtube.com/watch?v=FhEOyN8ceAE>\*

Eshelman s  
Statement and Testimony:

<https://www.gpo.gov/fdsys/pkg/CHRG-110hhr48587/html/CHRG-110hhr48587.htm>\*

Puma s Board does not believe that someone who was involved in clinical trial fraud that was  
uncovered by the FDA should be on the Board of Directors of a public company; particularly a  
company that is in the process of seeking FDA approval

\*Please paste the links above into your browser to view the content.

13  
Eshelman  
Continues to Demonstrate a  
Lack  
of Integrity (cont d)







